Regular coffee consumption (2-3 cups/day) protects against liver cirrhosis, reduces fibrosis, prevents liver cancer, and ...

The following is a summary of “Evaluating the GALAD Score for Detection of Hepatocellular Carcinoma in Patients With ...

Trans- versus cisgender adults have an increased prevalence of cirrhosis but similar five-year survival, according to a study ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment ...

Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosisalfapump® is ...

More information: Norbert Stefan et al, Metabolic dysfunction-associated steatotic liver disease: heterogeneous ...

US FDA grants fast track designation to Lipocine’s LPCN 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis: Salt Lake City Thursday, December 19, 2024, ...

LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the ...

Microbiome Changes in Chronic Liver Disease Highlight the Need for Personalized Treatment Nov. 18, 2024 — People with chronic liver disease have dramatic changes to the types and functions of ...